JP2020530465A - トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 - Google Patents

トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 Download PDF

Info

Publication number
JP2020530465A
JP2020530465A JP2020507090A JP2020507090A JP2020530465A JP 2020530465 A JP2020530465 A JP 2020530465A JP 2020507090 A JP2020507090 A JP 2020507090A JP 2020507090 A JP2020507090 A JP 2020507090A JP 2020530465 A JP2020530465 A JP 2020530465A
Authority
JP
Japan
Prior art keywords
protein
tfr
polypeptide
agent
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020507090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530465A5 (enExample
Inventor
マーク エス． デニス
マーク エス． デニス
ジェニファー ゲッツ
ジェニファー ゲッツ
アダム ピー． シルバーマン
アダム ピー． シルバーマン
ロバート シー． ウェルズ
ロバート シー． ウェルズ
ジョイ ユ ズチェロ
ジョイ ユ ズチェロ
ミハリス カリオリス
ミハリス カリオリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/018371 external-priority patent/WO2018152326A1/en
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2020530465A publication Critical patent/JP2020530465A/ja
Publication of JP2020530465A5 publication Critical patent/JP2020530465A5/ja
Priority to JP2023107814A priority Critical patent/JP2023123757A/ja
Priority to JP2025090730A priority patent/JP2025120209A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020507090A 2017-08-10 2018-08-10 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 Pending JP2020530465A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023107814A JP2023123757A (ja) 2017-08-10 2023-06-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
JP2025090730A JP2025120209A (ja) 2017-08-10 2025-05-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762543658P 2017-08-10 2017-08-10
US62/543,658 2017-08-10
US201762583314P 2017-11-08 2017-11-08
US62/583,314 2017-11-08
PCT/US2018/018371 WO2018152326A1 (en) 2017-02-17 2018-02-15 Engineered transferrin receptor binding polypeptides
USPCT/US2018/018371 2018-02-15
PCT/US2018/046337 WO2019033046A1 (en) 2017-08-10 2018-08-10 AFFINITY BASED METHODS FOR USING TRANSFERRIN RECEPTOR BINDING PROTEINS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023107814A Division JP2023123757A (ja) 2017-08-10 2023-06-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法

Publications (2)

Publication Number Publication Date
JP2020530465A true JP2020530465A (ja) 2020-10-22
JP2020530465A5 JP2020530465A5 (enExample) 2021-09-16

Family

ID=65272509

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020507090A Pending JP2020530465A (ja) 2017-08-10 2018-08-10 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
JP2020506964A Active JP7280241B2 (ja) 2017-08-10 2018-08-10 操作されたトランスフェリン受容体結合ポリペプチド
JP2023107814A Pending JP2023123757A (ja) 2017-08-10 2023-06-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
JP2025090730A Pending JP2025120209A (ja) 2017-08-10 2025-05-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020506964A Active JP7280241B2 (ja) 2017-08-10 2018-08-10 操作されたトランスフェリン受容体結合ポリペプチド
JP2023107814A Pending JP2023123757A (ja) 2017-08-10 2023-06-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
JP2025090730A Pending JP2025120209A (ja) 2017-08-10 2025-05-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法

Country Status (19)

Country Link
US (4) US20200369746A1 (enExample)
EP (2) EP3665194A4 (enExample)
JP (4) JP2020530465A (enExample)
CN (2) CN111094336A (enExample)
CA (2) CA3072051A1 (enExample)
DK (1) DK3665192T5 (enExample)
ES (1) ES2956062T3 (enExample)
FI (1) FI3665192T3 (enExample)
HR (1) HRP20231118T1 (enExample)
HU (1) HUE063021T2 (enExample)
LT (1) LT3665192T (enExample)
MD (1) MD3665192T2 (enExample)
PL (1) PL3665192T3 (enExample)
PT (1) PT3665192T (enExample)
RS (1) RS64584B1 (enExample)
SI (1) SI3665192T1 (enExample)
SM (1) SMT202300347T1 (enExample)
TW (1) TWI821197B (enExample)
WO (2) WO2019032955A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3583120T (pt) 2017-02-17 2022-12-15 Denali Therapeutics Inc Polipeptídeos de ligação ao recetor de transferrina manipulados
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP2021534220A (ja) * 2018-08-22 2021-12-09 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法
AU2020226754A1 (en) 2019-02-20 2021-09-16 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
IL293994A (en) 2019-12-23 2022-08-01 Denali Therapeutics Inc Progranulin variants, compositions comprising same and uses thereof
CN115279790A (zh) * 2020-01-13 2022-11-01 戴纳立制药公司 抗trem2抗体和其使用方法
CA3170338A1 (en) * 2020-02-19 2021-08-26 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
PE20231931A1 (es) 2020-10-14 2023-12-01 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas
US11827702B2 (en) 2021-09-01 2023-11-28 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
CA3242212A1 (en) * 2021-12-31 2023-07-06 Imnewrun Inc Blood-brain barrier permeable fusion protein and uses thereof
KR20250048010A (ko) 2022-07-29 2025-04-07 리제너론 파마슈티칼스 인코포레이티드 변형된 트랜스페린 수용체 좌위를 포함하는 비-인간 동물
JP2025528052A (ja) 2022-07-29 2025-08-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 脳及び筋肉へのトランスフェリン受容体（ｔｆｒ）媒介送達のための組成物及び方法
CN120865438A (zh) 2022-07-29 2025-10-31 瑞泽恩制药公司 重新靶向转铁蛋白受体1的病毒颗粒
US20240052051A1 (en) 2022-07-29 2024-02-15 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024130116A2 (en) * 2022-12-16 2024-06-20 Denali Therapeutics Inc. Methods and compositions related to engineered transferrin receptor‑binding molecules
US20250049896A1 (en) 2023-07-28 2025-02-13 Regeneron Pharmaceuticals, Inc. Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
WO2025029657A2 (en) 2023-07-28 2025-02-06 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500886A (ja) * 2010-11-30 2014-01-16 ジェネンテック， インコーポレイテッド 低親和性血液脳関門受容体抗体及びその使用
WO2016081640A1 (en) * 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
JP2016526878A (ja) * 2013-05-20 2016-09-08 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212365A2 (en) * 1999-08-30 2002-06-12 New York University School Of Medicine Crystal structures of domains of receptor protein tyrosine kinases and their ligands
CN101516907B (zh) * 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2879496C (en) * 2012-08-29 2024-01-09 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
BR112016015589A2 (pt) * 2014-01-06 2017-10-31 Hoffmann La Roche módulos de trânsito monovalentes para a barreira hematoencefálica
CN113621050A (zh) * 2014-05-22 2021-11-09 皮里斯制药有限公司 新型特异性结合多肽及其用途
CA2967830A1 (en) * 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
EP3221362B1 (en) * 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
IL302486A (en) * 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
US10457717B2 (en) * 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500886A (ja) * 2010-11-30 2014-01-16 ジェネンテック， インコーポレイテッド 低親和性血液脳関門受容体抗体及びその使用
JP2016526878A (ja) * 2013-05-20 2016-09-08 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
WO2016081640A1 (en) * 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use

Also Published As

Publication number Publication date
CN111148757A (zh) 2020-05-12
TWI821197B (zh) 2023-11-11
EP3665194A4 (en) 2021-07-07
WO2019032955A1 (en) 2019-02-14
TW201920278A (zh) 2019-06-01
US20200369746A1 (en) 2020-11-26
JP7280241B2 (ja) 2023-05-23
JP2020530293A (ja) 2020-10-22
JP2025120209A (ja) 2025-08-15
SMT202300347T1 (it) 2023-11-13
PL3665192T3 (pl) 2023-11-27
LT3665192T (lt) 2023-10-25
MD3665192T2 (ro) 2023-12-31
RS64584B1 (sr) 2023-10-31
EP3665192A1 (en) 2020-06-17
JP2023123757A (ja) 2023-09-05
EP3665194A1 (en) 2020-06-17
HUE063021T2 (hu) 2023-12-28
ES2956062T3 (es) 2023-12-12
FI3665192T3 (fi) 2023-09-28
US20240024432A1 (en) 2024-01-25
DK3665192T3 (da) 2023-10-09
EP3665192B1 (en) 2023-07-12
WO2019033046A1 (en) 2019-02-14
CA3072051A1 (en) 2019-02-14
CN111094336A (zh) 2020-05-01
DK3665192T5 (da) 2024-08-26
US20200289627A1 (en) 2020-09-17
SI3665192T1 (sl) 2023-11-30
CA3072035A1 (en) 2019-02-14
HRP20231118T1 (hr) 2023-12-22
PT3665192T (pt) 2023-09-25
US20230381286A1 (en) 2023-11-30
CN111148757B (zh) 2024-06-21

Similar Documents

Publication Publication Date Title
US20230381286A1 (en) Affinity-based methods for using transferrin receptor-binding proteins
US20250145729A1 (en) Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
US20220002436A1 (en) Anti-her2 polypeptides and methods of use thereof
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
US11884944B2 (en) Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
CN113785054A (zh) 包含艾杜糖醛酸2-硫酸酯酶的蛋白质分子制剂
CN116997364A (zh) 抗转铁蛋白受体融合蛋白及其使用方法
WO2024200988A1 (en) Tnfr2 binding polypeptides and methods of use
AU2024245891A1 (en) Abeta-targeting proteins and methods of use
TW202340459A (zh) 包含α—Ｌ—艾杜糖醛酸酶之融合蛋白及其方法
US20240392035A1 (en) Engineered anti-her2 bispecific proteins
EP4634218A2 (en) Methods and compositions related to engineered transferrin receptor-binding molecules
EP4499695A1 (en) Methods for treating brain glucose hypometabolism
HK40064377A (en) Formulations of protein molecules comprising iduronate 2-sulfatase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200409

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230301